Latest Conference Articles

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses the possibility of administering PD1 or PD-L1 blockades as a third-line or salvage therapy for patients with advanced lung cancer.

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses the significant advances with CDK4/6 inhibitors in the field of hormone receptor (HR)-positive breast cancer.

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the ongoing roles of regorafenib (Stivarga) and TAS-102 (Lonsurf) in colorectal cancer (CRC) treatment.

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the ongoing role and impact of regorafenib (Stivarga) in the paradigm of hepatocellular carcinoma (HCC) in an interview during the 2017 Chemotherapy Foundation Symposium.

Shaji Kumar, MD, professor of medicine, Mayo Clinic, discusses updates to the treatment paradigm of high-risk multiple myeloma in an interview during the 2017 Chemotherapy Foundation Symposium.

Cristiana Sessa, MD, head of Phase I-II Unit and Pharmacology, vice head of Medical Oncology and Head of Clinical Research, Oncology Institute of Southern Switzerland, discusses ataxia–telangiectasia and Rad3 related (ATR) inhibitors in patients with ovarian cancer who have BRCA-mutated tumors.

Ingfrid Haldorsen, MD, University of Bergen, Haukeland University Hospital, discusses the role of imaging in the diagnosis of endometrial cancer.

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses the results of the ARIEL3 trial in ovarian cancer.

Xavier Bosch, MD, MPH, Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia–Catalan Institute of Oncology, introduces a second-generation vaccination against the human papilloma virus (HPV) for the prevention of cervical cancer.

Umesh Mahantshetty, MD, MBBS, radiation oncologist, Tata Memorial Hospital, Mumbai, discusses the results of a trial of chemoradiation in patients with cervical cancer, presented at the 2017 International Meeting of the European Society of Gynaecological Oncology (ESGO).

Jalid Sehouli, MD, professor, director of the Clinic Campus Virchow and Campus Benjamin Franklin Charité Center Gynecology, Charité – Universitatsmedizin Berlin, discusses a trial of secondary cytoreductive surgery in patients with ovarian cancer, presented at the 2017 International Meeting of the European Society of Gynaecological Oncology (ESGO).

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses immunotherapy for patients with EGFR-mutated lung cancer.

Geoffrey R. Oxnard, MD, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the role of osimertinib (Tagrisso) in the TATTON trial for patients with lung cancer.

D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses unmet needs for patients with lung cancer.

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of MET in patients with lung cancer.

Rodabe N. Amaria, MD, department of Melanoma Oncology, division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses using genetically modified tumor infiltrating lymphocytes (TILs) in patients with advanced melanoma.

Dirk Schadendorf, MD, head of department for Dermatology, Venerology and Allergology, University Hospital Essen, Germany, discusses the efficacy of combining targeted therapy with checkpoint inhibitors for patients with melanoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses BRAF and MEK inhibitor combinations studies in melanoma.

Victoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses the Columbus trial for patients with melanoma.

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the use of nivolumab (Opdivo) in the adjuvant setting for the treatment of patients with melanoma.

Jason Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the combination approach of a PD-1 antibody plus an IDO inhibitor for patients with melanoma.

Alan Shain, PhD, postdoctoral scholar, UCSF School of Medicine, discusses the role of genetics in melanoma.

Adil Daud, MD, clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses challenges facing the treatment landscape of melanoma.

Marina Chiara Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses some of the recent exciting results regarding immunotherapy in non-small cell lung cancer (NSCLC).

Robert C. Doebele, MD, PhD, associate professor, Division of Medical Oncology, University of Colorado, discusses the significance of the results of a trial exploring entrectinib in patients with ROS1-positive non

Geoffrey R. Oxnard, MD, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses resistance mechanisms that occur in patients with EGFR-positive T790M non

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a study exploring entrectinib in patients with ROS1-positive, advanced or metastatic non-small cell lung cancer (NSCLC) during an interview at the IASLC 18th World Conference on Lung Cancer in Yokohama, Japan.

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, discusses the significance of the phase III FLAURA trial of first-line osimertinib (Tagrisso) in EGFR-mutant non-small cell lung cancer (NSCLC).

D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses the results of the ALTA trial, which is exploring brigatinib (Alunbrig) in patients with ALK-positive non-small cell lung cancer.

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring minimal residual disease in acute myeloid leukemia.